BIO Asia 2012 Plenary Session

  • Recommend
  • Tweet
  • Print
  • Email

The Next Frontier:  Asia in 5-10 Years

Wednesday, February 1st, 9:00am-10:00am

Asia has long been thought of as the next frontier for the biotech industry with large pharma and investors staking their claim over the last decade in Japan and more recently, in China. Korean biotech is rapidly becoming a real player as well, so what can we expect to see from this growing market in the next 5-10 years? Will the landscape evolve similarly to that of Europe and the US, with biotech epicenters, such as Boston and San Francisco? When will home-grown novel products reach market and which parts of Asia will they come from? Will sufficient capital markets exist to grow and sustain life sciences companies? Pharma executives, investors and other industry leaders will convene to discuss how the biotech landscape will evolve in Asia in the next 5-10 years.


  • David Flores, Co-Founder, President & CEO, BioCentury Publications, Inc.


  • Klaus Beck, PhD, MD, Vice President and Head of R&D Japan, AstraZeneca
  • Paul B. Bolno, MD, MBA , Vice President, Worldwide Business Development, Head of Asia, GlaxoSmithKline PLC
  • Joong Myung Cho, PhD, President & CEO, CrystalGenomics, Inc
  • Kewen Jin, Managing Director, Nimbus Innoworks

Who's Who

Klaus Beck, PhD, MD
Vice President and Head of R&D Japan, AstraZeneca
Klaus joined AstraZeneca in February 2010 as Vice President and Head of R&D Japan. Prior to AstraZeneca Klaus was at Amgen, where he held various roles including: head of R&D in Japan, medical affairs director in Europe, and he served in lead roles in translational research and early product development in the US. He has also been in research and development roles at Merck, Elan and Genentech.

Klaus has broad experience across all phases of drug discovery and development and in the therapeutic areas of neurology, psychiatry, hematology, supportive care oncology and inflammation. During his time as a discovery scientist, he has authored or co-authored over 30 publications, primarily in the area of neuroscience, including publications in Nature, Neuron and the Journal of Neuroscience.

Klaus was educated and trained in Germany, the UK and the US; he holds a M.D. and Ph.D. (Pharmacology) from the University of Heidelberg, and a Ph.D. (Neurobiology) from the University of Southern California in Los Angeles.

Paul Bolno, MD, MBA 
Vice President, Worldwide Business Development, Head of Asia, GlaxoSmithKline PLC

Paul is member of the Oncology Executive Team as well as the Oncology Commercial Board and Oncology Review Board in GlaxoSmithKline. He has developed and implemented the R&D business development strategy for the Oncology Business Unit. He has established and led a team of business development professionals responsible for applying scientific, financial and negotiating expertise to establish and maintain collaborations that facilitate the discovery, development and commercialization of innovative oncology medicines. He is also responsible for cultivating relationships with biotech/pharmaceutical companies, oncology key opinion leaders, venture capitalists, and academic institutions to identify emerging trends and partnering opportunities. He is also engaged in R&D cross therapeutic area leadership teams including the WWBD Executive Committee (BDEC), the Chairman of R&D’s Sounding Board and the coordination of R&D activity in Singapore.

Joong Myung Cho, Ph.D.
President & CEO, CrystalGenomics, Inc
Dr. Cho is the founder and president of CrystalGenomics, Inc., and has over 25 years of experience in biopharmaceutical industry from R&D to commercialization of novel pharmaceuticals.  He previously has served as the Executive Senior Vice President and Director of R&D Biotech Research Institute at LG Life Science (formerly LG Chem.). During his tenure, biopharmaceutical R&D at LG became the leading life sciences company in Korea where it grew from just a few research scientists to several hundreds prior to his departure. He has successfully introduced 10 different recombinant products such as growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha and gamma, GM-CSF, EPO, etc.  Moreover, four drug candidates were licensed out to multinational pharmaceutical companies under his supervision and one of them is approved by FDA (US). On the basis of such achievements, Dr. Cho has received many awards and acted as a member of governmental committees.  He received his Ph.D. from University of Huston and worked as a post-doc at the Baylor College of Medicine. Dr. Cho is an author of more 80 publications in books and journals including Nature, and an inventor of more than 200 filed patents.

David Flores 
Co-Founder, President & CEO, BioCentury Publications, Inc.
David has devoted more than 20 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder, Chairman & Editor-in-Chief Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.

Kewen Jin 
Managing Director, Nimbus Innoworks

Kewen Jin is a serial entrepreneur active in the China life science industry. He is currently Managing Director of Nimbus Innoworks, a life science incubator which aims to acquire and commercialize new technology and products in pharmaceuticals, medical devices, diagnostics and healthcare service. He was previously General Manager of Charles River Lab’s China company.  Kewen has co-founded several companies in pharmaceutical R&D services, drug discovery, and healthcare consulting, with one company listed in NYSE in 2010 and one acquired by a MNC company.  He is an Advisor to Suzhou Biobay, a leading life science park in China. He previously served as advisor to the Shanghai Pudong government in developing a life science industry cluster strategy. He also served as advisor to several MNC pharmaceutical, healthcare and investment companies.  He was a marketing and international operation executive with Wyeth fromm 1993 to 2000, in the U.S. and in China.  He was granted the 2005 Magnolia Award, the highest award the Shanghai government grants to individuals making major contribution to Shanghai. He served as the founding Chair of the Shanghai CRO Association. He also served on the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), the two leading Chinese professional organizations in the life science industry.  He was trained in medicine (Shanghai Jiaotong University School of Medicine), molecular biology (Rockefeller), and finance (Columbia).